Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Rucaparib · 1 trial · 7 indications
PFS by investigator was defined as the time from randomization to disease progression, according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Progressive disease was defined as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s).
PFS by investigator was defined as the time from randomization to disease progression, according to RECIST v1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Progressive disease was defined as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s).
PFS by investigator was defined as the time from randomization to disease progression, according to RECIST v1.1 as assessed by the investigator, or death due to any cause, whichever occurred first. Progressive disease was defined as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s).
| Arm | Type | Description |
|---|---|---|
| Arm A | EXPERIMENTAL | Oral rucaparib + intravenous (IV) nivolumab |
| Arm B | EXPERIMENTAL | Oral rucaparib + IV placebo |
| Arm C | EXPERIMENTAL | Oral placebo + IV nivolumab |
| Arm D | PLACEBO_COMPARATOR | Oral placebo + IV placebo |
| Japanese Open-label Safety Cohort | EXPERIMENTAL | Oral rucaparib + IV nivolumab |
| Name | Type | Description |
|---|---|---|
| Rucaparib | DRUG | Oral rucaparib will be administered twice daily |
| Nivolumab | DRUG | IV nivolumab will be administered once every 4 weeks |
| Placebo Oral Tablet | DRUG | Placebo tablets will be administered twice daily |
| Placebo IV Infusion | DRUG | IV placebo will be administered once every 4 weeks |
Inclusion Criteria: * Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or fol...
Rucaparib is being studied as maintenance treatment in patients with newly diagnosed epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, specifically those with FIGO stage III-IV disease who have achieved a partial or complete response to front-line platinum-based chemotherapy. It is currently in Phase 3 clinical development.
Rucaparib targets PARP1, PARP2, and PARP3, and it is a small molecule inhibitor of these enzymes. By inhibiting PARP proteins, it interferes with DNA repair mechanisms in cancer cells. This mechanism is being evaluated in the context of ovarian cancer maintenance therapy.
Rucaparib is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting a Phase 3 clinical trial of Rucaparib for the treatment of epithelial ovarian cancer.
Rucaparib is currently in Phase 3 clinical development. It is being investigated as a maintenance treatment for patients with newly diagnosed advanced ovarian cancer following response to front-line platinum-based chemotherapy. The drug is not yet approved for this indication and remains investigational.
Rucaparib is being evaluated in a Phase 3 clinical trial with the identifier NCT03522246. This study is assessing Rucaparib in combination with nivolumab as maintenance treatment in ovarian cancer patients who have responded to front-line platinum-based chemotherapy. The trial is active but not recruiting participants.
Rucaparib is also known by the ChEMBL identifier CHEMBL1173055. This identifier is used in chemical and biological databases to track the compound. No other alternative names have been established in the available information.